Formulary Exclusions & Non-FDA Compounded Medications

Formulary Exclusions & Non-FDA Compounded Medications

        (especially Low Dose Naltrexone and off-label use)


1. What “Formulary Exclusion” Means

A formulary is your insurance plan’s official list of covered medications.
If a medication is excluded, it means the insurer has chosen not to cover it under any circumstances — even with a prior authorization or appeal, unless a medical exception is granted.

Common Reasons for Exclusion

  • Cost containment: insurer has preferred “tiered” alternatives

  • Non-FDA approval: the medication or compounded formulation lacks FDA approval

  • Off-label use: prescribed for a condition not listed on the FDA label

  • Bulk powder compounding: the active ingredient is sourced in raw form rather than from a manufactured FDA-approved product

🔍 Example: Compounded Low Dose Naltrexone (LDN) is excluded from most Medicare Part D formularies because it’s not an FDA-approved finished drug and is considered “experimental or unproven” for many conditions — despite extensive clinical evidence supporting its off-label use.


2. Understanding Compounded & Non-FDA Medications

Compounded Medications

Compounding is when a pharmacist creates a medication tailored to the patient — adjusting the dose, removing allergens, or combining ingredients.

Why they’re often denied:

  • Not FDA-approved as a “finished” drug product

  • May be made using “bulk” (raw) powders not approved for that use

  • Insurers claim safety/efficacy cannot be guaranteed without FDA oversight

However, Medicare and private insurers can cover compounded drugs if:

  • Every active ingredient is part of an FDA-approved drug,

  • The compounded formula is “reasonable and necessary” for treatment,

  • It’s prescribed by a licensed provider and dispensed by a licensed pharmacy.


3. Off-Label Use & Why It Matters

Off-label use means a medication is prescribed for a condition or at a dosage not specifically listed on its FDA-approved labeling.
This practice is common and legal — the FDA regulates manufacturers, not physicians.

Insurers’ stance:
They often deny coverage for off-label uses unless:

  • Supported by recognized compendia (e.g., DrugDex, AHFS, NCCN), or

  • Backed by peer-reviewed medical evidence showing effectiveness for the diagnosed condition.

⚖️ Example: LDN (1.5 – 4.5 mg) is off-label because the FDA-approved form of naltrexone (50 mg) is for opioid/alcohol dependence — but off-label low-dose use is well-documented for autoimmune and inflammatory disorders.


4. How to Challenge Formulary & Compounding Denials

Step 1 – Request a Coverage Determination

Ask your plan in writing to reconsider coverage for the compounded or excluded medication.
Include:

  • Provider’s Letter of Medical Necessity

  • Supporting peer-reviewed studies

  • Explanation of why FDA-approved alternatives are not appropriate

Step 2 – File a Level 1 Appeal

If denied, submit an appeal citing:

  • Your plan’s obligation under CMS § 423.578 (Part D exception requests)

  • Supporting evidence from clinical literature

  • Any prior success or improvement with the medication

Step 3 – Escalate to Independent Review

Under Medicare Part D:

  • Level 1 → Redetermination by plan

  • Level 2 → Reconsideration by an Independent Review Entity (IRE)

  • Level 3 → Administrative Law Judge (ALJ) hearing (if over $180 in dispute)

🧾 AKG Advocacy Tip: Keep copies of every page — denials, evidence, provider statements, research articles — and label them clearly for your record or appeal packet.


5. Key Evidence to Include in Your Appeal

✅ Physician’s detailed Letter of Medical Necessity (diagnoses, dosage, treatment history)
✅ Published peer-reviewed studies supporting the off-label use
✅ Documentation of failure or intolerance to formulary alternatives
Pharmacy compounding log or verification of ingredient source (if available)
Patient statement describing impact and improvement


6. Example Denial Reason vs. Rebuttal

Denial ReasonHow to Respond
“Medication not FDA-approved.”Clarify that compounding from approved ingredients is permitted under 21 U.S.C. § 353a and is widely accepted in clinical practice.
“Use is experimental or investigational.”Cite peer-reviewed studies and recognized compendia demonstrating efficacy.
“Medication not on formulary.”Request a formulary exception under CMS guidelines citing lack of effective alternatives.
“Bulk ingredient not covered.”Provide evidence that compounded LDN uses pure naltrexone hydrochloride identical to FDA-approved product, only in adjusted dosage.

7. Real-World Example: Low Dose Naltrexone (LDN)

IssueInsurer ArgumentHow to Counter
Non-FDA-approved“LDN not an FDA-approved finished product.”Compounding from an FDA-approved ingredient is permitted; physician supervision ensures safety.
Off-label use“Not FDA-approved for autoimmune disease.”Cite studies on LDN’s immune-modulating and anti-inflammatory effects (e.g., Younger et al., Pain Med 2013).
Formulary exclusion“Excluded medication category.”File an exception request demonstrating no alternative provides equivalent benefit or tolerance.

Comments

Popular posts from this blog

Medicare vs. Medicare Advantage: What’s the Difference?

Top 10 Resources Every Patient Advocate Should Know

How to Prepare for a Doctor Appointment When You Have a Complex Condition